Innate Pharma
Clinical-stage biotech developing immunotherapies for cancer using the innate immune system.
IPH | PA
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Manufacturing
Description
Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-12-13 07:00 |
INNATE PHARMA PRÉSENTE UNE MISE À JOUR SUR L’ESSAI TELLOMAK DE LACUTAMAB
|
French | 123.7 KB | ||
| 2019-12-13 07:00 |
Innate Pharma Provides Update on Lacutamab Tellomak Trial
|
English | 126.4 KB | ||
| 2019-12-08 15:00 |
Innate Pharma présente Lumoxiti®, médicament approuvé par la FDA, au congrès de…
|
French | 224.7 KB | ||
| 2019-12-08 15:00 |
Innate Pharma highlights FDA-approved Lumoxiti® at ASH 2019
|
English | 295.1 KB | ||
| 2019-12-04 07:00 |
INNATE PHARMA RELEASES ITS FINANCIAL CALENDAR FOR 2020
|
English | 149.4 KB | ||
| 2019-12-04 07:00 |
INNATE PHARMA PUBLIE SON CALENDRIER FINANCIER POUR 2020
|
French | 186.1 KB | ||
| 2019-12-03 07:00 |
Innate Pharma certifiée Great Place to Work®
|
French | 178.7 KB | ||
| 2019-12-03 07:00 |
Innate Pharma Certified as a Great Place to Work®
|
English | 251.7 KB | ||
| 2019-11-13 07:00 |
Information financière du troisième trimestre 2019
|
French | 236.1 KB | ||
| 2019-11-13 07:00 |
Innate Pharma third quarter 2019 report
|
English | 211.2 KB | ||
| 2019-11-07 07:00 |
Innate Pharma partagera de nouvelles données de long terme sur Lumoxiti au cong…
|
French | 226.6 KB | ||
| 2019-11-07 07:00 |
Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society …
|
English | 375.2 KB | ||
| 2019-11-06 07:00 |
Innate Pharma announces preclinical data presentations at SITC 2019
|
English | 379.9 KB | ||
| 2019-11-06 07:00 |
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT NOVEMBER 1, 2019
|
English | 116.3 KB | ||
| 2019-11-06 07:00 |
Innate Pharma annonce la présentation de données précliniques au SITC 2019
|
French | 382.0 KB |
Automate Your Workflow. Get a real-time feed of all Innate Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Innate Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Innate Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
